Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Taylor

Showing results (331-340 of 335) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 335 results.
Nature Immunology|October 22, 2024
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseTom Thomas, Matthias Friedrich, Charlotte Rich-Griffin, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Nature Communications|March 11, 2022
Divergent trajectories of antiviral memory after SARS-CoV-2 infectionAdriana Tomic, Donal T Skelly, Ane Ogbe, et al.
Science (New York, N.Y.)|June 14, 2022
Immune boosting by B.1.1.529 <b>(</b>Omicron) depends on previous SARS-CoV-2 exposureCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Pageof 34

Showing results (331-340 of 335) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 335 results.
Nature Immunology|October 22, 2024
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseTom Thomas, Matthias Friedrich, Charlotte Rich-Griffin, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Nature Communications|March 11, 2022
Divergent trajectories of antiviral memory after SARS-CoV-2 infectionAdriana Tomic, Donal T Skelly, Ane Ogbe, et al.
Science (New York, N.Y.)|June 14, 2022
Immune boosting by B.1.1.529 <b>(</b>Omicron) depends on previous SARS-CoV-2 exposureCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Pageof 34